77.00
-0.20
(-0.26%)
At close: January 22 at 9:52:28 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in DKK | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 3 | 22 | 22 |
| Avg. Estimate | 83.03B | 79.74B | 287.76B | 347.26B |
| Low Estimate | 83.03B | 78.53B | 287.76B | 346.97B |
| High Estimate | 83.03B | 80.55B | 289.67B | 364.93B |
| Year Ago Sales | 65.86B | 65.35B | 232.26B | 287.76B |
| Sales Growth (year/est) | 26.06% | 22.02% | 23.89% | 20.68% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NOVA.F | -- | -- | -- | -- |
| S&P 500 | 9.39% | 11.29% | 14.06% | 13.54% |
Upgrades & Downgrades
| Upgrade | UBS: Sell to Buy | 1/8/2025 |
| Maintains | BMO Capital: Outperform to Outperform | 12/23/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 11/6/2024 |
| Maintains | Citigroup: Buy to Buy | 10/22/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 10/17/2024 |
| Maintains | Barclays: Overweight to Overweight | 10/16/2024 |
Related Tickers
LLY.F Eli Lilly and Company
725.30
+2.86%
PFE.DE Pfizer Inc.
25.41
-0.41%
AZN.L AstraZeneca PLC
11,040.00
-0.11%
GSK.L GSK plc
1,355.50
-0.22%
ROG.SW Roche Holding AG
273.80
+1.33%
NVS Novartis AG
98.17
-1.56%
BIIB Biogen Inc.
142.75
+1.26%
LLY Eli Lilly and Company
753.98
+1.57%
MRK Merck & Co., Inc.
95.68
-0.58%
PFE Pfizer Inc.
26.01
-2.36%